Can Statins Reduce Psoriasis Risk?
Gabriel Chodick, PhD, from Tel Aviv University in Israel, and colleagues analyzed data from 205,820 health plan enrollees (mean age 55 years; 54.1% female) who initiated statin treatment from January 1998 through September 2009. Over a mean of 6.2 years of follow-up, adherence with statins, measured by proportion of days covered (PDC) and diagnosis codes of psoriasis, were assessed.
The researchers found that a total of 5,615 psoriasis cases (incidence density, 4.4 per 1,000 person-years) were identified. Patients covered with statins for 40 to 59 percent of the time had a significantly (P<0.05) lower risk of psoriasis, with hazard ratios (HRs) of 0.84 and 0.74 among males and females, respectively, compared with non-adherent patients (PDC of <20%). For patients with PDC of ≥80% (more adherent), HRs were 0.88 (95% confidence interval, 0.79–0.98) and 1.00 (95% confidence interval, 0.90–1.11), respectively.
"The results of the current study suggest that high and long-term adherence with statins is not associated with a meaningful reduction in the risk of psoriasis," the authors write.